Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05167812
Other study ID # P_2022
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 1, 2022
Est. completion date February 1, 2028

Study information

Verified date December 2021
Source Leiden University Medical Center
Contact Angelos Youssef, MD
Phone +31715262896
Email a.youssef@lumc.nl
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Rationale: Recurrent pregnancy loss (RPL) is defined as the loss of two or more conceptions before the fetus reaches viability. It affects 1-3% of all fertile couples and despite extensive diagnostic work-up, in only around 30% an underlying cause is identified. Several factors may increase the risk for miscarriage, but the chance of a normal, successful pregnancy is still high. So, in supporting couples with RPL, an important part of the clinical management of these couples is to provide couples with accurate prognoses for their next pregnancy. The main limitation in current prediction models is the lack of a sufficiently large cohort, adjustment for relevant risk factors such that prognoses are individualized, and separating between the cumulative live birth rate and the chance that the next conception will lead to a live birth. In this project therefore we aim to make an individualized prognosis regarding the future chance of live birth and the chance of a healthy child. This could then lead to improved wellbeing and the ability of making future reproductive choices. Objectives: Primary objective: to predict the chance of a live birth within three years after intake in couples with unexplained RPL Secondary objectives: - to predict the chance of an ongoing pregnancy (>12 weeks) in the next pregnancy in couples with unexplained RPL. - to predict the chance of a complicated pregnancy in couples with unexplained RPL - to predict the chance dynamically of a live birth given the outcome of a pregnancy after intake - to predict the chance of above outcomes in couples with a known cause for RPL Study design: A multicenter retrospective and prospective cohort study. Study population: Couples with females aged ≤42 years in both prospective and retrospective inclusion. Retrospective inclusion: Couples with RPL who visited the RPL outpatient clinic in participating centers from 2006 until the start of this study. Prospective inclusion: new couples with RPL who will visit the clinic from 2021 onwards. Main study parameters/endpoints: - Pregnancy outcomes since intake - Time to pregnancy since intake - Time between pregnancies since intake - Pregnancy complications since intake - All outcomes will be obtained up to a maximum of five years after intake - Patient characteristics: cause for RPL, female age, male age, previous live birth, duration of RPL (since diagnosis) Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participating in this study does not yield any risks. There could be a burden in case of retrospectively collecting data. Participating does not yield direct benefits for the subjects, however it may lead to future improvements of care for couples with RPL.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1931
Est. completion date February 1, 2028
Est. primary completion date February 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 42 Years
Eligibility Inclusion Criteria: Couples that fulfill the following criteria are included (according to the ESHRE Recurrent Pregnancy Loss Guideline 2017): - RPL in the current relationship: defined as the loss of = 2 preceding pregnancies. These pregnancy losses include: - all pregnancy losses before the 24th week of gestation verified by ultrasonography or uterine curettage and histology - non-visualized pregnancies (including biochemical pregnancy losses and/or resolved and treated pregnancies of unknown location), verified by positive urine or serum hCG - both consecutive and non-consecutive pregnancy losses - Dutch or English speaking couple - Couples with females aged =42 years at intake Exclusion Criteria: - Mental or legal incapability of either the male or female of the couple - Loss of < 2 pregnancies in current relationship

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observation of pregnancies after intake
Monitoring pregnancies after intake at a dedicated recurrent pregnancy loss clinic to predict pregnancy success chances in couples with recurrent pregnancy loss

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Leiden University Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Live birth of RPL couples within three years assessed by ultrasound or hCG after intake at the RPL clinic 3 - 5 years
Secondary Pregnancy outcomes since intake (miscarriage, ongoing pregnancy, live birth) assessed by ultrasound, hCG, or "take home baby" miscarriages are assessed via ultrasound or pregnancy tests (positive test later followed by negative test). Ongoing pregnancy when ultrasound assessment is known but further follow up is missing, and live birth when pregnancy ends with the live birth of a child. 3 - 5 years
Secondary Time to pregnancy since intake measured in days Time that has passed since couple had an intake at the RPL clinic until first pregnancy, measured in days until the first day of the last menstruation of the first pregnancy after intake 3 - 5 years
Secondary Time between pregnancies since intake measured in days Time that has passed between each pregnancy a couple had since intake at the RPL clinic, measured in days between the end of the last pregnancy and until the first day of the last menstruation of the new pregnancy 3 - 5 years
Secondary Pregnancy complications since intake as registered by gynecologist or midwife All complications during pregnancy and during labor registered by caregiver (gynecologist or midwife) in all pregnancies after intake at the RPL clinic 3 - 5 years
See also
  Status Clinical Trial Phase
Completed NCT04718233 - Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss Phase 2
Recruiting NCT01946945 - Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis Phase 2
Completed NCT02572154 - Sperm DNA Fragmentation in Recurrent Pregnancy Loss N/A
Completed NCT03174951 - Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss Phase 2
Recruiting NCT05444283 - Genomic Predictors of Recurrent Pregnancy Loss
Active, not recruiting NCT04621773 - Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss
Recruiting NCT02990403 - The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss Phase 4
Recruiting NCT02990390 - The Epidemiology of Recurrent Spontaneous Abortion Associated With Thrombophilla N/A
Not yet recruiting NCT05612620 - Elucidating the Microbiome in Patients With Recurrent Pregnancy Loss
Not yet recruiting NCT05520112 - Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells Phase 1/Phase 2
Suspended NCT04397042 - SCUBE-1 and Carotid Intima Media Thickness in Recurrent Pregnancy Loss
Not yet recruiting NCT05341856 - Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL Early Phase 1
Recruiting NCT06007560 - Aerobe Cycling Training in Women With Unexplained Recurrent Pregnancy Loss N/A
Completed NCT02386384 - TNFα and MFG-E8: Novel Biomarkers to Predict Implantation Failure N/A
Recruiting NCT01635426 - Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages Phase 2/Phase 3
Suspended NCT01546350 - Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH Phase 2
Completed NCT00721591 - Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy N/A
Terminated NCT00564174 - Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT N/A
Completed NCT04455256 - Evaluation of Endoplasmic Reticulum Stress in Patients With Recurrent Pregnancy Loss
Not yet recruiting NCT05237843 - Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss Phase 1